We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CD38xCD3

News List

Glenmark to launch trial in solid tumours for its CD38xCD3 bispecific antibody GBR 1342 expressbpd
November 10, 2018
The decision to expand clinical development of GBR 1342 was based on a recently completed ex vivo translational study in multiple solid tumours utilising the clinically validated CANscript platform, where treatment with GBR 1342 revealed predictive respon
Glenmark to launch trial in solid tumours for its CD38xCD3 bispecific antibody GBR 1342 expressbpd
November 10, 2018
The decision to expand clinical development of GBR 1342 was based on a recently completed ex vivo translational study in multiple solid tumours utilising the clinically validated CANscript platform, where treatment with GBR 1342 revealed predictive respon